Summary of Verastem Oncology Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $25.1 million for Q2 2026, reflecting a strong rebound in sales.

Cost of Sales: $3.8 million, in line with revenue growth.

License Revenue: $15 million milestone payment from Secura Bio for COPIKTRA sales.

R&D Expenses: $41.3 million, driven by ongoing clinical trials.

SG&A Expenses: $27.4 million, consistent with prior quarter, reflecting ongoing commercial activities.

Non-GAAP Adjusted Net Loss: $30.6 million ($0.31 per share), improved from a loss of $41.3 million ($0.62 per share) in Q2 2025.

Cash Position: Ended Q2 with $136.4 million; pro forma cash balance of $201.4 million after accounting for new financing.

2Strategic Updates and Business Highlights

Commercial Strategy: Focus on increasing new patient starts, expanding use earlier in treatment, and ensuring patients remain on therapy.

Product Adoption: Positive trends in physician confidence and patient refills noted, with significant growth in new prescribers.

Pipeline Development: Advancements in the VS-7375 program, including FDA fast-track designation for non-small cell lung cancer and initiation of three Phase II registration-directed studies.

Royalty Financing: Secured up to $75 million in non-dilutive funding, enhancing financial flexibility.

3Forward Guidance and Outlook

Self-Sustaining Business: Expectation that the LGSOC business will become self-sustaining by the end of 2026.

Upcoming Data: Anticipate a comprehensive update on VS-7375 in October, including response rates across three lead tumor types.

Continued Growth: Confidence in sustaining momentum in CO-PACK sales into Q3 and beyond.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: Concerns regarding the competitive pressures in the KRAS G12D space, particularly with other inhibitors emerging.

Clinical Trial Risks: The need to demonstrate superior efficacy and tolerability compared to existing treatments may pose challenges.

Market Dynamics: Potential variability in patient adherence and treatment duration could impact future sales.

5Notable Q&A Insights

Partnership Activity: Ongoing discussions regarding partnerships in the G12D space, particularly with Erasca, but no finalized agreements yet.

Response Rate Expectations: The company maintains a target of 30% overall response rate and six months of durability for FDA accelerated approval, which aligns with industry benchmarks.

Differentiation Strategy: Emphasis on the tolerability profile of VS-7375 compared to other treatments, with a focus on minimizing side effects.

Commercial Segmentation: Growth attributed to both new patient starts and improved duration of therapy, with a balanced focus on both academic and community settings. This summary encapsulates the key aspects of Verastem Oncology's Q2 2026 earnings call, highlighting financial performance, strategic initiatives, and outlook while addressing potential challenges and insights from the Q&A session.